Overview Financials News + Filings Key Docs Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results Appointed director
|
PROKIDNEY CORP.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/10/2023 |
8-K
| Quarterly results
Docs:
|
"ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights WINSTON-SALEM, N.C. – August 10, 2023 – ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease , today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. “In the second quarter, and throughout the first half of 2023, we steadily advanced our REACT development programs, including our initial Phase 3 study, proact 1, that is assessing the potential for REACT to delay or halt the progression of moderate to severe diabetic CKD,” said Dr. Tim Bertram, Chief Executive Officer of ProKidney. “Looking ahead, we expect to reach s..." |
|
05/11/2023 |
8-K
| Quarterly results
Docs:
|
"ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights WINSTON-SALEM, N.C. – May 11, 2023 – ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease , today announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments. “During the first quarter of 2023, we continued to advance the Phase 3 clinical development of REACT® to assess its potential to delay and possibly eliminate the need for dialysis, and in parallel we sharpened our plans for manufacturing and organizational development as we progress toward potential commercialization,” said Dr. Tim Bertram, Chief Executive Officer of ProKidney. “Patient enrollment in proact ..." |
|
|
|